An examination of global and regional Opioid consumption trends 1980-2011

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 28, Issue 3, 2014, Pages 259-275

  Hastie, Barbara A ^a   Gilson, Aaron M ^b   Maurer, Martha A ^c   Cleary, James F ^d  

^a Researcher and Policy Analyst ^*  (United States)

^b Senior Scientist and Research Program Manager   (United States)

^c Policy Program Manager and Researcher   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Global pain disparities; Opioid accessibility; Opioid availability; Opioid consumption; Pain; WHO Regions

Indexed keywords

FENTANYL; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; PETHIDINE; NARCOTIC ANALGESIC AGENT;

DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG INDICATION; DRUG USE; DRUG UTILIZATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DISPARITY; HUMAN; PAIN; REVIEW; TRANSDERMAL PATCH; TREND STUDY; WORLD HEALTH ORGANIZATION; AFRICA; ANALGESIA; EPIDEMIOLOGY; EUROPE; SOUTHEAST ASIA; SOUTHERN EUROPE; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; WESTERN HEMISPHERE;

AFRICA; AMERICAS; ANALGESICS, OPIOID; ASIA, SOUTHEASTERN; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; EUROPE; HEALTHCARE DISPARITIES; HUMANS; MEDITERRANEAN REGION; MORPHINE; PAIN MANAGEMENT;

EID: 84906818321     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2014.941132     Document Type: Review

References (74)

1. Worldwide Palliative Care Alliance,World Health Organization. Global Atlas of Palliative Care at the End of Life. London: Worldwide Palliative Care Alliance; 2014.
2. World Health Assembly. Strengthening of palliative care as a component of comprehensive care throughout the life course. WHA67.19; [Geneva, Switzerland] 24 May 2014.
3. Kachroo S, Etzel CJ. Decreasing the cancer burden in developing countries: concerns and recommendations. Eur J Cancer Care. 2009;18:18-21.
4. International Association for the Study of Pain. Declaration of Montreal. Seattle, WA: International Association for the Study of Pain; 2010.
5. Breivik, H. Prevalence and impact of chronic pain: a systematic review of epidemiological studies on chronic pain. Presented at the 11thWorld Congress of the International Association for the Study of Pain; Sydney, Australia; August 21-26, 2005.
6. Duthey B, ScholtenW. Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. J Pain SymptomManage. 2014;47:283-297.
7. Seya MJ, Gelders SFAM, Achara OU, Milani B, Scholten WK. A first comparison between the consumption of and the need for opioid analgesics at country, regional and global level. J Pain Palliat Care Pharmacother. 2011;25:6-18.
8. World HealthOrganization. Cancer Pain Relief: With aGuide to Opioid Availability. 2nd ed. Geneva, Switzerland:World Health Organization; 1996.
9. Breitbart W, Cortes-Ladino A. Pain in human immunodeficiency virus disease. In: Fishman SM, Ballantyne JC, Rathmell JP, eds. Bonicas Management of Pain. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2010;827-845.
10. World Health Organization, HIV/AIDS Department. Priority Interventions: HIV/AIDS Prevention, Treatment and Care in the Health Sector. Geneva, Switzerland: World Health Organization; 2010.
11. World Health OrganizationHIV-AIDS. Palliative Care. Geneva, Switzerland: World Health Organization; 2004.
12. World Health Organization. Cancer Pain Relief. Geneva, Switzerland: World Health Organization; 1986.
13. World Health Organization. WHO Guidelines on the Pharmacological Treatment of Persisting Pain in Children With Medical Illnesses. Geneva, Switzerland: World Health Organization; 2012.
14. World HealthOrganization. EssentialMedicines-WHO Model List. 1st ed. Geneva, Switzerland: World Health Organization; 1977.
15. World Health Organization. WHO Model List of Essential Medicines. 18th ed. Geneva, Switzerland: World Health Organization; 2013.
16. Hogerzeil HV, Liberman J, Wirtz VJ, et al. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet. 2013;381:680-689.
17. World Health Organization. Achieving Balance in National Opioids Control Policy: Guidelines for Assessment. Geneva, Switzerland: World Health Organization; 2000.
18. World Health Organization. Ensuring Balance in National Policies on Controlled Substances: Guidance for Availability and Accessibility of Controlled Medicines. Second and revised edition. Geneva, Switzerland:World Health Organization; 2011.
19. United Nations. Single Convention on Narcotic Drugs, 1961. Geneva, Switzerland: United Nations; 1961.
20. United Nations. Single Convention On Narcotic Drugs, 1961, As Amended by the 1972 Protocol Amending the Single Convention on Narcotic Drugs, 1961. New York: United Nations; 1972.
21. Cherny NI, Cleary J, Scholten W, Radbruch L, Torode J. The Global Opioid Policy Initiative (GOPI)) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction andmethodology. AnnOncol. 2013;24:7-13.
22. Cleary J, Powell RA, Munene G, et al. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Africa: a report from the Global Opioid Policy Initiative (GOPI)). Ann Oncol. 2013;24:14-23.
23. Cleary J, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Asia: a report from the Global Opioid Policy Initiative (GOPI)). Ann Oncol. 2013;24:24-32.
24. Cleary J, Simha N, Panieri A, et al. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in India: a report from the Global Opioid Policy Initiative (GOPI)). Ann Oncol. 2013;24:22-40.
25. Cleary J, De Lima L, Eisenchlas J, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Latin America and the Caribbean: a report from the Global Opioid Policy Initiative (GOPI)). Ann Oncol. 2013;24:41-50.
26. Cleary J, Silbermann M, Scholten W, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in theMiddle East: a report from the Global Opioid Policy Initiative (GOPI)). Ann Oncol. 2013;24:51-59.
27. Cleary J, Radbruch L, Torode J, Cherny NI. Next steps in access and availability of opioids for the treatment of cancer pain: reaching the tipping point? Ann Oncol. 2013;24:60-64.
28. United Nations Information Service. INCB Reviews availability of medicines and prevention of drug abuse worldwide. UNIS/NAR/1212, Vienna, Austria, United Nations, June 2, 2014.
29. Silbermann M. Current trends in opioid consumption globally and in Middle Eastern countries. J Pediatr Hematol Oncol. 2011;33:S1-S5.
30. Silbermann M. Opioids in Middle Eastern populations. Asian Pac J Cancer Prev. 2010;11(Suppl 1):1-5.
31. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med. 2011;5:e13-e22.
32. Green CR, Ndao-Brumblay SK, West B, Washington T. Differences in prescription opioid analgesic availability: comparing minority and white pharmacies across Michigan. J Pain. 2005;6:689-699.
33. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical/DefinedDaily Dose.Oslo, Norway:Norwegian Institute of Public Health; 2007.
34. Vignaroli E, Bennett MI, Nekolaichuk C, et al. Strategic pain management: the identification and development of the IAHPC opioid essential prescription package. J Palliat Med. 2012;15:186-191.
35. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-e68.
36. National Institute for Health and Clinical Excellence. Opioids in Palliative Care: Safe and Effective Prescribing of Strong Opioids for Pain in Palliative Care of Adults. NICE Clinical Guideline 140. Manchester, UK: National Institute for Health and Clinical Excellence; 2012.
37. Miaskowski C, Cleary J, Burney R, et al. Guideline for theManagement of Cancer Pain in Adults and Children. APS Clinical Practice Guidelines Series, No. 3. Glenview, IL: American Pain Society; 2005.
38. Svendsen K, Borchgrevink PC, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med. 2011;25:725-732.
39. Chinellato A, Terrazzani G,Walley T, Giusti P. Opioids in Italy: is marketing more powerful than the law? Lancet. 2003;362:78.
40. De Conno F, Ripamonti C, Brunelli C. Opioid purchases and expenditure in nine western European countries: Are we killing off morphine?. Palliat Med. 2005;19:179-184.
41. Chinellato A, Skaper SD, Giusti P, Debetto P. Consumption of opioid analgesics in Italy: light at the end of the tunnel? Eur J Pain. 2011;15:220-221.
42. Garć?a del Pozo J, Carvajal A, Viloria JM, Velasco A, Garcia del Pozo V. Trends in the consumption of opioid analgesics in Spain: higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol. 2008;64:411-415.
43. Jarlbaek L, Andersen M, Hallas J, Engholm G, Kragstrup J. Use of opioids in a Danish population-based cohort of cancer patients. J Pain Symptom Manage. 2005;29:336-343.
44. Hudec R, Tisonova J, Foltan V, Kristova V. Consumption of three strong opioids (morphine, oxycodone and fentanyl) in seven European countries during seven years (2003-2009). Bratisl Lek Listy. 2013;114:581-583.
45. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain. 2009;13:954-962.
46. American Association of Oral and Maxillofacial Surgeons. AAOMS parameters of care: clinical practice guidelines for oral and maxillofacial surgery. J OralMaxillofacial Surg. 2012;70(11, Suppl):1-320.
47. Kitching AJ, ONeill SS. Fast-track surgery and anaesthesia. Contin Educ Anaesth Crit Care Pain. 2009;9:39-43.
48. Guagnozzi D, Lucendo AJ. Colorectal cancer surveillance in patients with inflammatory bowel disease: what is new? World J Gastrointest Endcosc. 2012;4:108-116.
49. American Society for Gastrointestinal Endoscopy. Communications from the ASGE Standards of Practice Committee: sedation and anesthesia in GI endoscopy. Gastrointest Endosc. 2008;68:815-818.
50. Lambert R. Endocsopy in screening for digestive cancer. World J Gatrointest Endcosc. 2012;4:518-525.
51. Davies AN. Breakthrough cancer pain. Curr Pain Headache Rep. 2014;18:420-428.
52. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013;46:619-628.
53. Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013;46:573-580.
54. Muller-Schwefe G, Ahlbeck K, Aldington D et al. Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements. Curr Med Res Opin. 2014;1-14. Epub: June 10, 2014; doi:10.1185/03007995. 2014.925439.
55. Corli O, Roberto A. Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain. A review article. Minerva Anestesiol, epub Dec 17, 2013; PMID: 24346227.
56. Teoh N, Vainio A. The status of pethidine in the WHO Model List of Essential Drugs. Palliat Med. 1991;5:185-186.
57. World HealthOrganization. EssentialMedicines-WHO Model List. 15th ed. Geneva, Switzerland:World Health Organization; 2007.
58. VanZee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health. 2009;99:221-227.
59. BreivikH, Collett B, Ventafridda V, Cohen R,Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333.
60. Zin CS, Chen LC, Knaggs RD. Changes in trends and pattern of strong opioid prescribing in primary care. Eur J Pain. 2014;10-2149.
61. Fischer B, Jones W, Krahn M, Rehm J. Differences and overtime changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf. 2011;20:1269-1277.
62. Sullivan MD, Edlund MJ, Fan MY, DeVries A, Brennan BJ, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138:440-449.
63. Gilson AM, Maurer MA, Ryan KM, Rathouz PJ, Cleary JF. Using a morphine equivalence metric to quantify opioid consumption: examining the capacity to provide effective treatment of debilitating pain at the global, regional, and country levels. J Pain Symptom Manage. 2013;45:681-700.
64. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med. 2011;25:402-409.
65. Vallerand AH, Riley-Doucet C, Hasenau SM, Templin T. Improving cancer pain management by homecare nurses. Oncol Nurs Forum. 2004;31:809-816.
66. Vallerand AH. The use of long-acting opioids in chronic pain management. Nurs Clin North Am. 2003;38:435-445.
67. De Lima L, Krakauer EL, Lorenz KA, Praill D, MacDonald N, Doyle D. Ensuring palliative medicine availability: the development of IAHPC list of essential medicines for palliative care. J Pain Symptom Manage. 2007;33:521-526.
68. Fallon M, Cherny NI, Hanks G. Opioid analgesic therapy. In: Hanks G, Cherny NI, Christakis NA, Fallon M, Kaasa S, Portenoy RK, eds. Oxford Textbook of Palliative Medicine. 4th ed. New York: Oxford University Press; 2010:661-698.
69. Inturrisi CE, Lipman AG. Opioid analgesics. In: Ballantyne JC, Rathmell JP, Fishman SM, eds. Bonicas Management of Pain. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2010;1172-1187.
70. Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD003868. DOI: 10.1002/14651858.CD003868.pub3.
71. Cherny NI, Baselga J, De Conno F, Radbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol. 2010;21:615-626.
72. De Lima L, Sweeney C, Palmer JL, Bruera E. Potent analgesics are more expensive for patients in developing countries: a comparative study. J Pain Palliat Care Pharmacother. 2004;18: 59-70.
73. Joranson DE, Ryan KM, Maurer MA. Opioid policy, availability and access in developing and nonindustrialized countries. In: Fishman SM, Ballantyne JC, Rathmell JP, eds. Bonicas Management of Pain. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2010:194-208.
74. Foley KM, Wagner JL, Joranson DE, Gelband H. Pain control for people with cancer and AIDS. In: Jamison DT, Breman JG, Measham AR, et al., eds. Disease Control Priorities in Developing Countries. 2nd ed. New York: Oxford University Press; 2006:981-993.